Haemonetics Corporation Q3 2026 Earnings Recap

HAE Q3 2026 February 5, 2026

Get alerts when HAE reports next quarter

Haemonetics Corporation reported strong third-quarter results for Fiscal Year 2026, raising full-year guidance for revenue, earnings, and free cash flow, driven by robust growth in Blood Management Technologies and Plasma.

Earnings Per Share Beat

$1.31 vs $1.27 est.

+3.1% surprise

Revenue Beat

339000000 vs 331919700 est.

+2.1% surprise

Market Reaction

1-Day -8.74%

5-Day -11.35%

30-Day +0.94%

See HAE alongside your other holdings

Add to your portfolio — free

Key Takeaways

Third-quarter revenue reached $339 million, with organic growth ex CSL of 8% in the quarter and 10% year-to-date.
Adjusted earnings per share increased by 10% to $1.31, reflecting durable earnings quality.
Blood Management Technologies grew 8% in the quarter, bolstered by TEG 6s disposable sales and hemostasis management.
Plasma segment performance saw a dramatic organic growth of 20%, supported by strong demand and share gains, prompting an uptick in full-year revenue guidance.
Hospital business organic growth guidance adjusted to approximately 4%, now anticipated at the low end of the previous range.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit HAE on AllInvestView.

Next Q4 2026